Dako, Quintiles Partner on Personalized Rx; First Project to Focus on AstraZeneca Cancer Rx | GenomeWeb

Dako and Quintiles announced this week that they would work together to develop personalized medicine products, with the first of their projects focused on supporting AstraZeneca's development of an oncology drug.

As part of the non-exclusive alliance, "Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products," the companies said in a statement. "The first such collaboration will support AstraZeneca in the development of one of its leading oncology compounds."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.